

## References

I-107

1. Skirven TM, Bachoura A, Jacoby SM, et al. The effect of a therapy protocol for increasing correction of severely contracted proximal interphalangeal joints caused by Dupuytren disease and treated with collagenase injection. *J Hand Surg Am.* 2013;38(4):684-689.
2. Witthaut J, Jones G, Skrepnik N, et al. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. *J Hand Surg Am.* 2013;38(1):2-11.
3. Xiaflex REMS (risk evaluation and mitigation strategy). Auxilium Pharmaceuticals, Inc. Dec 2013. [xiaflexrems.com](http://xiaflexrems.com).
4. REMS Training Guide for Administering Xiaflex for Peyronie's Disease. Auxilium Pharmaceuticals, Inc. December 2013. [xiaflexrems.com](http://xiaflexrems.com).
5. Coleman S, Gilpin D, Kaplan TD, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple dupuytren contractures. *J Hand Surg Am.* 2014;39(1):57e64.
6. Peimer CA, Wilbrand S, Gerber RA, et al. Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture. *J Hand Surg Eur.* Apr 29 2014;40(2):141-149.
7. Sood A, Therattil PJ, Paik AM, et al. Treatment of Dupuytren disease with injectable collagenase in a veteran population: A case series at the Department of Veterans Affairs New Jersey Health Care System. *Eplasty.* 2014;14:e13.
8. Hurst L, Gaston G, Brown RA, et al. Prospective multicenter, multinational study to evaluate the safety and efficacy of concurrent collagenase clostridium histolyticum injections to concurrently treat two dupuytren's contractures in the same hand. *JHS.* 2014;39(9):e32-e33.
9. Egui Rojo MA, Moncada Iribarren I, Carballido Rodriguez J, Martinez-Salamanca JI. Experience in the use of collagenase clostridium histolyticum in the management of Peyronie's disease: current data and future prospects. *Ther Adv Urol.* 2014;6(5):192-197.
10. Jordan GH, Carson CC, Lipshultz LI. Minimally invasive treatment of Peyronie's disease: Evidence-based progress. *BJU Int.* 2014;114:16-24.
11. Cervero SR, Ferrando FN, Jornet PJ. Use of resources and costs associated with the treatment of Dupuytren's contracture at an orthopedics and traumatology surgery department in Denia (Spain): Collagenase clostridium hystolyticum versus subtotal fasciectomy. *BMC Musculoskelet Disord.* 2013;14:293.
12. Levine LA, Cuzin B, et al. Clinical safety and effectiveness of collagenase clostridium histolyticum injection in patients with Peyronie's disease: A phase 3 open-label study. *J Sex Med.* 2015;12:248-258.

13. Murphy L, Murphy K, Kilpatrick S, Thompson N. The use of Collagenase Clostridium Histolyticum in the management of Dupuytren's contracture – outcomes of a pilot study in a District General Hospital setting. *Ulster Med J.* 2017;86(2):94-98.
14. Hayes, Inc. Hayes Medical Technology Directory Report. Xiaflex (collagenase Clostridium histolyticum) for Dupuytren Contracture. Lansdale, PA: Hayes, Inc.; March 2017. Accessed January 19, 2018.
15. Peyronie's Disease Unabridged Guidelines. American Urological Association Web site. Published 2015. Accessed January 18, 2018.
16. Peimer C, Blazar P, Coleman S, et al. Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data. *J Hand Surg Am.* 2015;40:1597-1605.